Loading…
Based on limited available metadata, the FDA issued a Warning Letter to Infuscience, Inc. (operating as Bioscrip Infusion Services) on December 21, 2020, regarding drug products. The specific violations are unclear due to unavailable subject line details, though the company's infusion services business suggests potential concerns related to drug preparation, sterility, or compounding practices. This action falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the available metadata.